Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Emergent BioSolutions выглядит как недорогая по мультипликаторам, но пока не полностью убедительная по качеству прибыли история восстановления. P/E 5.7, P/S 0.57, P/B 0.74 и P/FCF 11.3 заметно ниже медианы отрасли, что поддерживает тезис о потенциальной недооценке. При этом низкие мультипликаторы частично объясняются слабой и нестабильной прибылью: EPS TTM отрицательный, net income по TTM равен нулю, а прогнозный EPS тоже остаётся очень скромным. Рентабельность выглядит смешанно: operating margin около медианы отрасли, gross margin 56.1% выглядит неплохо, но ROE, ROA и ROI всё ещё ниже отраслевых ориентиров. Динамика маржинальности за последние периоды была неровной: в середине года показатели улучшались, но затем ослабли, что снижает уверенность в устойчивости восстановления. Ликвидность, напротив, сильная: current ratio 5.01 и quick ratio 2.41 дают хороший запас прочности по краткосрочным обязательствам. Долговая нагрузка остаётся заметной проблемой, поскольку debt/equity 1.09 существенно выше медианы отрасли, а долгосрочный долг около 663 млн долл. при умеренной капитализации создаёт финансовый рычаг и повышает чувствительность к операционным сбоям. Баланс в целом не выглядит слабым: денежные средства 249 млн долл., собственный капитал 583 млн долл. и активы 1.461 млрд долл. обеспечивают определённую устойчивость. Выручка и EBITDA по отдельным периодам показывали способность генерировать операционный результат, но абсолютные значения прибыли и операционного дохода остаются нестабильными. Дивидендов нет, поэтому акционер не получает дополнительной поддержки через распределение капитала. В сумме фундаментал скорее поддерживает умеренно позитивный взгляд на оценку из-за дешёвых мультипликаторов и ликвидности, но слабая прибыльность и повышенный долг ограничивают потенциал переоценки. Для инвестора это история с возможным апсайдом при дальнейшем улучшении качества earnings, но пока без достаточных оснований для агрессивного повышения целевой оценки.

Emergent BioSolutions Inc.

Сильный индекс, незначительно упал. Быки в растерянности.

Strong index, slightly down. The bulls are confused.

Средний индекс, значительно вырос. Рынок на стороне быков.

Medium index, significantly up. The market is on the bulls' side.

Слабый индекс, незначительно вырос. Приток средств в лонги остается на невысоком уровне.

Weak index, slightly up. The inflow of funds into longs remains at a low level.

Акция выглядит дешёвой по мультипликаторам и ликвидной, но слабая и нестабильная прибыльность вместе с повышенным долгом сдерживают переоценку.

Data is currently not available
Edit My Quotes
Add up to 25 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data
Data is currently not available
Edit My European Quotes
Add up to 25 instruments
To add instruments:
Type a instrument or company name. When the instrument you want to add appears, add it to My European Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple instruments separated by spaces.
These instruments will be available throughout the site during your session.
Save data
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Continue
Data is currently not available
Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Save data

Emergent (EBS) Q4 2025 Earnings Transcript

(RTTNews) - Emergent BioSolutions (EBS) announced that the FDA has approved its supplemental New Drug Application for over-the-counter NARCAN Nasal Spray to be packaged in a new carrying case, which includes two blister packs. The company said the NARCAN carrying case will be made available soon to purchase for consumers nationwide at select retailers and online, as well as public interest customers through NARCANDirect, Emergent's ordering and distribution platform.
The company noted that, since the prescription launch of NARCAN Nasal Spray in 2016, more than 85 million doses have been distributed across the U.S. and Canada.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Emergent BioSolutions: FDA Approves SNDA For NARCAN Carrying Case

In trading on Monday, auto dealerships shares were relative laggards, down on the day by about 2.2%. Helping drag down the group were shares of America's Car-Mart, off about 4.3% and shares of AutoZone, down about 3.9% on the day.
Also lagging the market Monday are biotechnology shares, down on the day by about 2.1% as a group, led down by Emergent BioSolutions, trading lower by about 15.4% and Silence Therapeutics, trading lower by about 8.1%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Monday Sector Laggards: Auto Dealerships, Biotechnology Stocks

Data is currently not available
Edit My Quotes
Add up to 25 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Data is currently not available
Edit My European Quotes
Add up to 25 instruments
To add instruments:
Type a instrument or company name. When the instrument you want to add appears, add it to My European Quotes by selecting it and pressing Enter/Return.
Copy and paste multiple instruments separated by spaces.
These instruments will be available throughout the site during your session.
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Data is currently not available
Edit Watchlist
Add up to 20 symbols
To add symbols:
Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.
Copy and paste multiple symbols separated by spaces.
These symbols will be available throughout the site during your session.
Data is currently not available
Opt in to Smart Portfolio
We are currently experiencing technical difficulties, please try again.
Smart Portfolio is supported by our partner TipRanks. By connecting my portfolio to TipRanks Smart Portfolio I agree to their Terms of Use.

Emergent BioSolutions (EBS) Earnings Transcript

Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript

(RTTNews) - Below are the earnings highlights for Emergent BioSolutions Inc (EBS):
Earnings: -$31.3 million in Q4 vs. -$49.5 million in the same period last year. EPS: -$0.58 in Q4 vs. -$0.95 in the same period last year. Excluding items, Emergent BioSolutions Inc reported adjusted earnings of $2.6 million or $0.05 per share for the period.
Revenue: $194.7 million in Q4 vs. $276.6 million in the same period last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Emergent BioSolutions Inc Q4 Earnings Summary

Gilead Sciences (GILD) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of $1.67 per share. This compares to earnings of $1.72 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 13.77%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.58 per share when it actually produced earnings of $2.02, delivering a surprise of 27.85%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Gilead, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $7.57 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 7.27%. This compares to year-ago revenues of $7.12 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Gilead shares have added about 3.4% since the beginning of the year versus the S&P 500's gain of 3.1%.
What's Next for Gilead?
While Gilead has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Gilead: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.82 on $6.66 billion in revenues for the coming quarter and $7.59 on $28.27 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Emergent Biosolutions (EBS), another stock in the same industry, has yet to report results for the quarter ended December 2024.
This biopharmaceutical company is expected to post quarterly loss of $0.35 per share in its upcoming report, which represents a year-over-year change of +54.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Emergent Biosolutions' revenues are expected to be $252.61 million, down 8.7% from the year-ago quarter.
Should You Invest in Gilead Sciences, Inc. (GILD)?
Before you invest in Gilead Sciences, Inc. (GILD), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates

Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.67 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.70 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 14.38%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $1.49 per share when it actually produced earnings of $1.80, delivering a surprise of 20.81%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Bristol Myers, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $12.34 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 6.59%. This compares to year-ago revenues of $11.48 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Bristol Myers shares have added about 5.6% since the beginning of the year versus the S&P 500's gain of 3.1%.
What's Next for Bristol Myers?
While Bristol Myers has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Bristol Myers: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.66 on $11.32 billion in revenues for the coming quarter and $6.98 on $46.32 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Emergent Biosolutions (EBS), has yet to report results for the quarter ended December 2024.
This biopharmaceutical company is expected to post quarterly loss of $0.35 per share in its upcoming report, which represents a year-over-year change of +54.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Emergent Biosolutions' revenues are expected to be $252.61 million, down 8.7% from the year-ago quarter.
Should You Invest in Bristol Myers Squibb Company (BMY)?
Before you invest in Bristol Myers Squibb Company (BMY), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report
Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Bristol Myers Squibb (BMY) Beats Q4 Earnings and Revenue Estimates

An analyst initiated coverage of Emergent BioSolutions (NYSE: EBS) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. On the news, they piled into the stock, ultimately sending it to a nearly 12% gain on the day. That contrasted very favorably to the stumbling S&P 500 (SNPINDEX: ^GSPC), which ended Monday down 1%.
More than an emerging company
Emergent, which benefits from a wider-than-average range of revenue-generating activities, is now being tracked by H.C. Wainwright's Raghuram Selvaraju. He launched his coverage with a buy recommendation at a price target of $15 per share. That is 62% higher than the stock's current level, even after that almost 12% increase.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. See the 10 stocks »
According to reports, Selvaraju believes Emergent is well diversified in its offerings, and it is active in several medical segments that have fine potential for growth. He feels the company's Narcan opioid reversal spray will continue to experience heavy demand due to the continuing epidemic of such drugs in the U.S.
The analyst also waxed bullish about the company's vaccines business, pointing out that it has jabs for monkeypox and smallpox. The former has been in the news lately as a possible global healthcare threat.
A stock to consider as we move into 2025
News of Sevaraju's fresh and positive take on Emergent puts a nice cap on the company's 2024. Heading into next year, with various illnesses that might become the next pandemic, it's well positioned to be a frontline soldier in the next worrying healthcare emergency.
Even if that doesn't occur, the analyst's view that Emergent's business is well (and effectively) diversified is accurate. This alone makes the stock worthy of consideration as a buy.
Should you invest $1,000 in Emergent BioSolutions right now?
Before you buy stock in Emergent BioSolutions, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Emergent BioSolutions wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $839,670!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
See the 10 stocks »
*Stock Advisor returns as of December 30, 2024
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Emergent BioSolutions. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Periodand min./max. price, $	Price change, %		Volatility, %		Volume, $
Periodand min./max. price, $	EBS	Industry	EBS	Industry	Volume, $
Yesterday 9.0 - 9.7	-5.10	3.52	11.07	1.97	4.25M
Week 8.7 - 9.7	4.72	1.02	5.07	4.05	28.49M
Month 7.5 - 9.7	8.34	2.17	16.71	7.99	92.03M
3 Months 7.5 - 11.5	-17.94	12.66	47.00	15.32	329.14M
6 Months 7.5 - 14.1	-16.36	8.80	67.99	20.77	758.31M
Year 5.3 - 14.1	56.36	22.85	81.52	35.28	1.76B
3 years 1.4 - 15.1	-13.58	14.23	204.35	67.49	6.82B
5 years 1.4 - 68.0	-84.40	69.63	228.40	98.19	13.92B
All time 1.4 - 137.6	-16.72	138.03	—	—	23.26B

Emergent BioSolutions Inc.

Price and volatility history

Risk ratios